RPL23AP95

Across TCGA pan-cancer cohorts, RPL23AP95 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of RPL23AP95’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where RPL23AP95 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL23AP95 is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

BLCA, HNSC, and STAD are the cancer types where RPL23AP95 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL23AP95 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+0.343	.002	8	view →
HNSC	All	All	+0.233	<.001	8	view →
STAD	All	II,III,IV	+0.663	<.001	4	view →
KIRP	Male	II,III,IV	+0.372	.004	4	view →
LUSC	All	All	+0.311	<.001	4	view →
LIHC	Male	All	+0.251	<.001	4	view →
BRCA	All	All	+0.204	.010	4	view →
THCA	Male	All	−0.491	.013	3	view →
UCEC	All	IV	−0.600	.002	2	view →
READ	All	III,IV	−0.545	.023	2	view →
CHOL	All	All	+0.427	.005	2	view →
COAD	Female	All	+0.381	.023	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

RPL23AP95–BLCA

Open the BLCA breakdown →